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Background: In July 2011, the Malawi national HIV program implemented the integrated antiretroviral therapy
(ART) and prevention of mother-to-child transmission (PMTCT) guidelines. Among the principle goals of the
guidelines were increasing ART uptake among TB/HIV co-infected patients and treating TB/HIV patients with a
different drug regimen. We, therefore, assessed the effects of the new guidelines on ART uptake, the factors
associated with ART uptake and the frequency of ARV-related adverse events in TB/HIV co-infected patients.
Methods: This was an observational cohort study using routine program data. All ART-naïve adult TB/HIV
co-infected patients starting TB treatment over the six months preceding and following implementation of 2011
integrated ART/PMTCT guidelines were included.
Results: A total of 685 adult TB/HIV co-infected patients were registered in the study; 377 (55%) before and 308
(45%) after the implementation of the new guidelines. ART uptake increased from 70% (240/308) before implementation
of the new guidelines to 78% (262/377) after the inception of the new guidelines (P=0.013). The proportion of TB
patients initiating ART within two weeks of starting TB treatment increased from 30% before implementation of
the new guidelines to 46% after implementation of the new guidelines (p <0.001). The median time from the start
of TB treatment to ART initiation dropped from 16 days (IQR 14-31) before the new guidelines to 14 days (IQR 9-20;
p = 0.004) after implementing the new guidelines. Factors associated with ART uptake were enrolment in HIV care
before starting TB treatment and being a retreatment TB patient. The overall frequency of ARV-related adverse events
was higher in patients on d4T/3TC/NVP (35%) than those on TDF/3TC/EFV (25%) but not significantly different (P=0.052).
Conclusion: Implementation of the 2011 Malawi Integrated ART/PMTCT guidelines was associated with an overall
increase in ART uptake among TB/HIV patients and with an increase in the number of patients initiating ART within two
weeks of starting their TB treatment. However, the reduction in time between initiating TB treatment and starting ART
was small suggesting that further measures must be implemented to facilitate ART uptake. Early enrolment in HIV care
provides opportunities for timely ART initiation among TB patients.
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Human immunodeficiency virus (HIV) and tuberculosis
(TB) are the two of the major epidemics in sub-Saharan
Africa. In 2010, the TB/HIV co-infection rate in TB pa-
tients was about 44% in the African region and as high
as 82% in high TB/HIV burden countries [1]. The TB
case-fatality rate is between 16% and 35% in TB/HIV co-
infected individuals not receiving antiretroviral therapy
(ART) in Africa [2].
Previous studies showed reductions in HIV-associated
mortality and morbidity among TB/HIV co-infected in-
dividuals who start ART early [3,4]. Recent clinical trials
demonstrated that early initiation of ART was safe, and
was associated with increased survival [5-7]. In 2010, the
World Health Organisation (WHO) revised guidelines
reflecting this growing body of evidence [8]. These guide-
lines recommend initiation of ART among TB/HIV co-
infected patients, irrespective of CD4 cell count, within
eight weeks of starting TB treatment.
Malawi, a poor landlocked country in Africa, is severely
affected by the dual epidemic of HIV and TB. In 2012, the
estimated incidence of TB was 163 persons per 100,000
population [9] and HIV prevalence among TB patients
was 66%, resulting in a considerable proportion of early
deaths in individuals on ART attributed to undiagnosed
TB [10]. With this high TB burden, the performance of
the national TB programme is negatively impacted.
The use of ART results in reduction in rates of TB in
HIV cohorts [11,12]. Malawi embarked on rapid scale up
of ART in 2004 and, by 2012, almost 390,000 individuals
were alive and on ART. Despite such remarkable pro-
gress in the provision of ART, only 46% of TB/HIV pa-
tients started ART while on TB treatment in 2010 [13],
mainly due to the limited integration of TB and HIV ser-
vices. In July 2011, the Malawi national HIV program
adopted the 2010 WHO guidelines and implemented
treatment guidelines (Malawi Integrated Guidelines for
Clinical Management of HIV, 2011, First Edition [14]) to
increase access to quality ART and PMTCT services. For
the treatment of TB/HIV infection, the guidelines rec-
ommend the initiation of ART within two weeks of the
start of TB treatment and the provision of the antiretro-
viral drugs (ARVs) Tenofovir, Lamividine and Efavirez
(TDF/3TC/EFV) to ART-naïve patients. Also, the guide-
lines recommend both the provision of Isoniazid pre-
ventive therapy (IPT) for pre-ART patients to reduce the
incidence of TB, and intensified TB case finding (ICF)
for all patients in pre-ART and ART follow-up to enable
early diagnosis and treatment of TB. Since its implemen-
tation, it is unclear whether the guidelines have led to an
increase in the overall proportion of TB/HIV patients
starting ART during TB treatment and within two weeks
of initiation of TB treatment, and, ultimately, improved
TB treatment outcomes. In addition, there is limitedinformation on the comparative effects of the ARV regi-
mens given to TB/HIV patients based on the Malawi na-
tional ART/PMTCT guidelines. We, therefore, assessed
the effects of the national guidelines on ART uptake in
TB patients, and the factors associated with ART uptake
at the largest TB registration centre in Malawi. We docu-
mented the ARV regimen that TB patients received and
compared the frequency of ARV-related adverse events be-
tween TB/HIV co-infected individuals initiating a Stavudine,
Lamivudine and Nevirapine (D4T/3TC/NVP) ARV drug re-
gimen to those initiating a TDF/3TC/EFV regimen.
Methods
Study design
We conducted an observational cohort study using routine
program data. All ART-naïve adult TB/HIV co-infected
patients who started TB treatment and were managed at
Martin Preuss Centre (MPC) over the six months pre-
ceding and following implementation of 2011 integrated
Malawi national ART/PMTCT guidelines were eligible for
inclusion in the study. The study period extended from
January 2011 to December 2011.
Setting
The study was conducted at MPC, the largest TB registra-
tion site in the country. MPC is an integrated TB/HIV
clinic located in Malawi’s capital city, Lilongwe. The clinic,
described in detail previously [15], functions in partner-
ship with the Lilongwe District Hospital and has three
units: HIV testing and counselling, ART, and TB; the latter
unit includes sputum submission. Almost 66% of the TB
patients in Lilongwe are registered at MPC. Approxi-
mately 3,200 TB patients are registered annually at the
clinic. HIV ascertainment among TB patients is 95%. Diag-
nosis of TB is based on clinical examination, sputum
smear microscopy, chest radiography and other investi-
gations as appropriate for extra-pulmonary disease. Once
diagnosed with TB, patients are recorded in the national
TB register by the district TB officer. TB treatment is initi-
ated at MPC but patients can choose to complete their
treatment at one of the 18 peripheral health facilities in
Lilongwe District.
TB/HIV co-infected patients are started on ART regard-
less of CD4 cell count. Before implementation of the new
ART/PMTCT guidelines in July 2011, TB/HIV co-infected
patients were initiated on a regimen of d4T/3TC/NVP;
from July 2011, patients were initiated on TDF/3TC/EFV.
TB/HIV co-infected patients are seen monthly for clinical
assessment and collection of their ARVs and TB drugs. At
each clinic visit, patients are screened for common symp-
toms and ARV-related adverse events using a symptom/
drug side-effect checklist comprising of anaemia, jaundice,
lactic acidosis, hepatitis, peripheral neuropathy, diarrhoea,
abdominal pain and skin rash. TB treatment outcomes
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up, treatment failure and died) are updated in the TB paper
registers. TB and ART services are completely integrated;
HIV-positive and HIV-negative TB patients are managed by
the same clinical officers.
Data collection and statistical analysis
Data were extracted from the clinic’s electronic data sys-
tem and from TB registers and analysed in Stata 12.0.
Descriptive analysis was used to explore the proportion
of TB/HIV co-infected patients starting ART and devel-
oping ARV-related adverse events. In the time-to-event
analysis, patient were entered in the analysis at the time
of TB registration and observation time ended either
at the time of ART initiation, death, lost to follow-up,
transfer to other TB facility or completion of TB treat-
ment, whichever came first. We estimated the cumulative
probability of starting ART while accounting for competing
risk of death. Competing risks proportional hazards regres-
sion models were used to estimate the adjusted associa-
tions of patient characteristics and implementation of new
guidelines and time to ART initiation. For the purpose of
this study, we considered only adverse events registered as
resulting from ARVs according to the clinical officer’s or
physician’s clinical judgment. For the analyses, the first
occurrence of each adverse event was considered the end
point of the outcome. We compared the frequency of
ARV-related adverse events between TB/HIV co-infected
individuals initiating a D4T/3TC/NVP drug regimen and
those initiating a TDF/3TC/EFV drug regimen using the
chi-square test. A level of significance of P ≤ 0.05 was used.
Ethical considerations
The study was approved by the Malawi National Health
Science Research Committee in Lilongwe, Malawi, and
The Union Ethic Advisory Board in Paris, France. As the
study used routine programme data, both ethics boards
provided a waiver of individual informed consent. Data
for the study did not include any personal identifiers.
Results
Study population
A total of 1,069 adult TB/HIV co-infected patients were
registered for TB treatment during the study period, of
which 384 (36%) were excluded as they were already on
ART. Of the remaining 685 (64%) study participants,
377 (55%) started TB treatment before the implemen-
tation of the new ART/PMTCT national guidelines and
308 (45%) started after implementation of the guidelines.
There were no significant differences in sex, median age
at TB registration, TB classification and TB category in
the study participants who started TB treatment before
and after implementation of the new ART guidelines
(Table 1).ART uptake before and after implementation of the new
guidelines
The proportion of patients starting ART while on TB
treatment increased from 70% (262/377) before imple-
mentation of the new guidelines to 78% (240/308) after
implementation (p = 0.013) (Table 1). After implementa-
tion of the new guidelines, by two weeks after the start of
their TB treatment, 46% of TB patients had started ART,
compared to 30% before implementation (p <0.001). A
total of 115 TB patients registered before implementation
of the new guidelines were not started on ART; of these,
97 (84%) did not start ART although they were in care
throughout their TB treatment, 13 (11%) died, 4 (3%)
transferred to other TB facilities and 1 (<1%) was lost to
follow-up. After implementation of the new guidelines, 68
of the newly registered TB patients did not start ART; of
these, 61 (90%) were in care throughout their TB treat-
ment, 3 (4%) died, 3 (4%) transferred to other TB facilities
and 1 (1%) was lost to follow-up. The median time to
ART initiation after the start of TB treatment dropped
from 16 days (IQR 14–31) before implementation of the
new guidelines to 14 days (IQR 9–20; p = 0.004) after im-
plementation. Figure 1 shows the cumulative probability
of starting ART up to 6 months after initiating TB treat-
ment, accounting for competing risks. The probability of
starting ART at 2 weeks and 2 months after initiating TB
treatment increased from 32% and 58% to 40% and 64%,
respectively, after implementation of the new guidelines.
After controlling for gender, age, TB classification,
time of enrolment in HIV care and TB patient category,
patients starting TB treatment after the implementa-
tion of the 2011 national ART/PMTCT guidelines were
1.38 (95% CI 1.15-1.65) times more likely to start ART
compared to TB/HIV patients registered before imple-
mentation of the new guidelines (Table 2). Patients in
HIV care at the start of their TB treatment were more
likely to be initiated on ART than patients not in HIV
care at the start of their TB treatment (adjusted subha-
zard ratio 1.72; 95% CI 1.36-2.18).
ARV regimens and ARV-related adverse events
A total of 502 patients started ART during their TB treat-
ment. All patients starting ART before the implementation
of the 2011 national ART/PMTCT guidelines received the
D4T/3TC/NVP drug regimen. After implementation of
the guidelines, 174 (61%) of TB/HIV patients received the
TDF/3TC/EFV drug regimen and 110 (39%) of patients
received the D4T/3TC/NVP drug regimen. ARV drug
regimen was not recorded in 4 patients registered prior to
implementation of the new guidelines.
We explored the ARV-related adverse events recorded
during the ART follow-up visits among the 284 TB/HIV
patients who started ART after implementation of the
national guidelines. The median follow-up time was
Table 1 Characteristics of HIV-infected individuals with tuberculosis registered at MPC before and after implementation of
the 2011 Malawi national ART/PMTCT guidelines, January 2011 and December 2011
Before (n = 377) After (n = 308) P-value
Female (%) 132 35% 106 34% 0.870
Age (years) Median (IQR) 34 (29–40) 34 (29–39) 0.459
15-34 204 54% 157 51% 0.413
35+ 173 46% 151 49%
Type of TB₣
Extrapulmonary 88 25% 65 22% 0.545
Smear-positive pulmonary 104 29% 83 28%
Smear-positive pulmonary 164 46% 149 50%
TB categoryβ
New 341 91% 282 92% 0.646
Retreatment 33 9% 24 8%
HIV test£
Before TB diagnosis 208 60% 167 56% 0.312
After TB diagnosis 141 40% 133 44%
Enrolled in HIV care
Before TB diagnosis 53 14% 59 18% 0.084
After TB diagnosis 336 86% 262 82%
Started ART
By 2 weeks 112 30% 142 46% <0.001
By 6 month 257 68% 237 77% 0.013
Total 262 70% 240 78% 0.013
₣32 had missing data on TB types, β5 had missing data TB category, £36 had unknown time of HIV test.
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up, 5 stopped ART, 49 transferred out to other TB facil-
ities and 19 died. A total of 88 ARV-related adverse events
were observed in 82 (29%) patients (Table 3). The overall
frequency of ARV-related adverse events was higher inFigure 1 Time from start of TB treatment to initiation of ART
among HIV patients receiving TB treatment at Martin Preuss
Centre Clinic, pre- and post-implementation of the 2011 Malawi
ART/PMTCT guidelines.patients on the d4T/3TC/NVP regimen (35%) than those
on the TDF/3TC/EFV regimen (25%), but not significantly
different (P = 0.052). Peripheral neuropathy was more fre-
quent among patients on the D4T/3TC/NVP drug regimen
than among those on the TDF/3TC/EFV regimen (22% vs
9%). Vomiting was more common among patients on the
D4T/3TC/NVP regimen than among patients on the TDF/
3TC/EFV regimen (10% vs 4%). We also noted a case of
hepatitis and one case of jaundice in patients on the TDF/
3TC/EFV regimen. The ARV drug regimen was changed in
3 (2%) and 8 (10%) patients on the TDF/3TC/EFV regimen
and the D4T/3TC/NVP regimen, respectively.
Discussion
This is the first formal evaluation of the effect of the
2011 Malawi national ART/PMTCT guidelines on ART
uptake, factors associated with ART uptake and use of
the TDF/3TC/EFV regimen in TB/HIV patients. Imple-
mentation of the new guidelines was associated with an
increase in ART uptake in TB patients. However, the
reduction in time to starting ART was marginal. The
prevalence of ARV-related toxicities was higher in pa-
tients receiving the D4T/3TC/NVP drug regimen than
those receiving the TDF/3TC/EFV regimen and more
Table 2 Competing risk regression modelling of time from TB initiation to starting ART in TB patients co-infected with
HIV at MPC, January 2011 and December 2011
Characteristics N (%) SHR€ (95% CI) Adjusted SHR€ (95% CI)
Guideline change
Before 377 (55%) 1 (ref) 1 (ref)
After 308 (45%) 1.34 (1.13 – 1.61) 1.38 (1.15–1.65)
Sex
Male 447 65%) 1 (ref) 1 (ref)
Female 238 (35%) 0.87 (0.72 – 1.04) 0.87 (0.71–1.06)
Age (years) 685 0.99 (0.98 – 1.01) 0.99 (0.98–1.00)
Type of TB₣
Extrapulmonary 153 (23%) 1.15 (0.92 – 1.43) 1.16 (0.92–1.46)
Smear–positive pulmonary 187 (29%) 1.04 (0.84 – 1.29) 1.04 (0.84–1.30)
Smear–positive pulmonary 313 (48%) 1 (ref) 1 (ref)
TB patient category
New 623 (92%) 1 (ref) 1 (ref)
Retreatment 57 (8%) 0.70 (0.52 – 0.95) 0.66 (0.49–0.91)
Enrolled in HIV care
Before TB diagnosis 107 (16%) 1.77 (1.43 – 2.20) 1.72 (1.36–2.18)
After TB diagnosis 578 (84%) 1 (ref) 1 (ref)
SHR€ = SubHazard ratios ₣45 PTB had unknown smear results; 5 cases had missing data for TB patient category.
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men. These findings support the feasibility and safety of
initiating ART early in TB/HIV co-infected patients and
the use of the recommended TDF/3TC/EFV regimen in
real-life clinical settings.
After implementation of the 2011 national integrated
ART/PMTCT guidelines, there was an increase (from
30% to 46%) in the proportion of patients initiating ART
within two weeks of the start of their TB treatment and
an increase in the overall ART uptake among TB pa-
tients from 70% to 78%. We believe that the increased
ART uptake and reduced time to ART initiation was dueTable 3 Distribution of ARV-related adverse events by ARV d
Malawi£
ARV-related adverse effects Total (n = 284)
Total with one or more ARV-related adverse events* 82 29%
Anorexia 6 2%
Leg pain/numbness 40 14%
Jaundice 1 0%
Skin rash 9 3%
Vomit 22 8%
Hepatitis 1 0%
Abdominal pain 5 2%
Fever 5 2%
Other 9 3%
*P-value = 0.052; £ARV = antiretroviral.to the implementation of these new guidelines. During
the study period, there were no major concurrent inter-
ventions in TB patients apart from the implementation
of the guidelines. Although the overall national burden
of TB patients co-infected with HIV has been decreasing
over the years, the proportion of TB patients co-infected
with HIV remained constant at the study site (65%) dur-
ing the study period. Furthermore, both ascertainment
of HIV and enrolment in HIV care prior to TB registra-
tion were similar before and after implementation of the
guidelines. Even before the implementation of the new
guidelines, MPC, unlike most TB/ART clinics in Malawi,rug regimen among TB patients receiving ART at MPC,
d4T/3TC/NVP (n = 110) TDF/3TC/EFV (n = 174)
39 35% 43 25%
2 2% 4 2%
24 22% 16 9%
0 0% 1 1%
5 5% 4 2%
4 4% 18 10%
0 0% 1 1%
2 2% 3 2%
2 2% 3 2%
5 5% 4 2%
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treatment [15], which meant that TB patients at MPC
already had a shorter than average waiting period to ini-
tiate ART. Therefore, although we observed a significant
increase in ART uptake in TB patients at MPC after im-
plementation of the new guidelines, the effect of the
guidelines might have been obscured. Nevertheless, the
national recommendation probably encouraged more
rapid initiation of ART in TB patients among whom
there may be a high mortality rate.
Similar to other studies [16,17], even after the imple-
mentation of the new guidelines, a sizeable proportion
(22%) of TB/HIV co-infected patients did not start ART,
suggesting the need for clinic-based interventions.
Among those who did not initiate ART, 90% did not
start ART in spite of being in care throughout their TB
treatment. Also, the reduction in the time between TB
registration and initiation of ART start was marginal and
may not necessarily have had clinical benefits. The find-
ings clearly indicate that the tracking of patients through
the continuum of care must be improved. Intensified
educational efforts aimed at reminding the TB clinic
staff and patients about the importance of ART and ad-
dressing stigma and fear, and also better clinic patient
flow are needed to improve ART uptake. Even as the up-
take of ART among TB/HIV co-infected is scaled up,
much morbidity and mortality in TB/HIV patients could
be prevented by applying the “Three I’s”: intensified case
finding, infection control, and isoniazid preventive ther-
apy. In Malawi’s national HIV programme, pre-ART and
ART patients are screened for TB during their follow-
up. By June 2013, 94% of all patients retained on ART
had been screened for TB at their last clinic visit and
58% of all patients retained in pre-ART care had re-
ceived IPT.
Our results also showed an independent association
between being in HIV care and starting ART. TB pa-
tients who were in HIV care prior to TB registration
were more likely to start ART compared to those who
enrolled in HIV care after TB registration. One possible
explanation is those patients who were already in HIV
care might have been easier to track through the con-
tinuum of care and to get started on ART. Thus, in-
creasing early HIV testing and enrolment in HIV care
would likely provide opportunities for timely ART initi-
ation and prevention of TB disease. Retreatment TB pa-
tients were less likely to start ART, possibly because of
the model of TB/ART service delivery at the clinic. All
retreatment TB patients are admitted in a TB ward for
two months. This TB ward is separate from the MPC
TB outpatient clinic, and ART services are not provided on
the ward. Thus, these patients are only offered ART after
their two months of intensive TB treatment. Provision of
ART services to TB patients admitted on the TB wardwould not only facilitate ART uptake among this category
of patients but also improve their TB treatment outcomes.
Almost 39% of TB/HIV co-infected patients were initi-
ated on the D4T/3TC/NVP regimen after implementation
of the revised Malawi national ART/PMTCT guidelines.
The new guidelines recommend the D4T/3TC/NVP re-
gimen for ART-naïve adult TB/HIV co-infected patients
with anaemia (with haemoglobin levels of < 8 g/dl); how-
ever, none of the TB patients in this study who started on
the D4T/3TC/NVP regimen had documented anaemia.
Co-administration of the D4T/3TC/NVP regimen and the
rifampicin-containing anti-tuberculosis therapy containing
may lead to drug interactions. Previous studies showed a
reduction in the levels of NVP in the presence of rifam-
picin [18], possible loss of virologic capabilities and in-
creased drug resistance [19,20]. It is therefore important
for all ART providers to follow the new national treatment
guidelines and ensure that all TB/HIV co-infected patients
are started on the recommended TDF/3TC/EFV regimen.
Almost a quarter of the patients in this study developed
ARV-related adverse events during the follow-up period.
The prevalence of adverse events was higher in patients
on the D4T/3TC/NVP regimen than in patients on the
TDF/3TC/EFV regimen and more patients on the D4T/
3TC/NVP regimen were switched to the other ARV regi-
mens, suggesting the comparative safety of the TDF/3TC/
EFV regimen in this population. Peripheral neuropathy
and vomiting were frequently reported adverse events.
Neuropathy is usually caused by D4T and may be more
likely when D4T and isoniazid are co-administered [21].
With the observed high prevalence of neuropathy, it is
likely that the neuropathy was induced by co-administering
of D4T and isoniazid. Due to short and long term toxicity
of D4T, the Malawi integrated ART/PMTCT guidelines
specifically recommends TDF. Considering the high preva-
lence of neuropathy, the D4T containing regimen should
only be given when no alternative options are available.
Due to high cost, provision of the TDF-based regimen oc-
curred in phases. In phase one, it was recommended that
the TDF regimen only be given to TB/HIV co-infected pa-
tients, and pregnant and lactating women starting ART for
PMTCT. In phase two, rolled out in July 2013, all HIV-
infected individuals eligible for ART would receive the TDF
based regimen. The findings in this study generally support
the move to providing a TDF-based regimen to all HIV-
infected individuals.
The results of this study should be viewed with the fol-
lowing limitations. The retrospective, observational nature
of the study design is a limitation as data were solely based
on medical records and, therefore, prone to data incom-
pleteness. As previously reported [22,23], medical profes-
sionals may wrongly record adverse events reported by
patients; this can lead to either under- or over-estimation
of the event frequency. Moreover, since the ascertainment
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verse events might have been missed, which would have
led to an underestimation of the prevalence of adverse
events. Despite these limitations, the study findings are
useful to inform programme planning in Malawi and other
comparable settings to improve care for TB/HIV patients.
Conclusion
Implementation of the 2011 Malawi ART/PMTCT guide-
lines on ART initiation of TB patients was associated with
increased ART uptake. However, the reduction in time be-
tween initiating TB treatment and starting ART was small,
suggesting that further measures must be implemented to
facilitate ART uptake. Being in HIV care prior to the start
of TB treatment was associated with increased ART up-
take. Increasing the early enrolment in HIV care of all
HIV-positive individuals would provide greater opportun-
ities for timely ART initiation among TB/HIV co-infected
patients. The use of the TDF/3TC/EFV regimen appeared
to be safer than the D4T/3TC/NVP regimen in TB/HIV
patients, however, further evaluations and laboratory mon-
itoring of ART patients on recommended TDF/3TC/EFV
regimen would be beneficial in documenting adverse drug
events and tolerability of the regimen.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
HT, AJ conceived the study. HT, AJ, ABS, MK, WN contributed to the study
design. HT drafted the manuscript and AJ, ABS, EM, WN, LG, MK, SP critically
revised the manuscript. All authors gave approval of the final version to be
published.
Authors’ information
Hannock tweya is supported as an operational research fellow by the
International Union Against Tuberculosis and Lung Disease, Paris, France.
Acknowledgements
The authors would like to thank all the staff who collected data at Martin
Preuss Center clinics. We thank numerous donors supporting the Martin
Preuss Center clinics. The donors had no role in study design, data collection
and analysis, decision to publish, or preparation of the manuscript. No
additional external funding was received for this study.
Author details
1The International Union Against Tuberculosis and Lung Disease, Paris,
France. 2The Lighthouse Trust, P.O. Box 106, Lilongwe, Malawi. 3Institute of
Social and Preventive Medicine, University of Bern, Bern, Switzerland.
4Department of Biomedical Informatics, University of Pittsburg, P.O. Box
31563, Lilongwe, Malawi. 5Central Monitoring and Evaluation Division/
Department for HIV and AIDS, Ministry of Health, Lilongwe, Malawi.
6International Training and Education Center for Health (I-TECH), Lilongwe,
Malawi. 7University of Washington, Seattle, USA.
Received: 31 March 2013 Accepted: 13 February 2014
Published: 20 February 2014
References
1. World Health Organisation: Global tuberculosis control report 2011. Geneva:
World Health Organisation, WHO/HTM/TB/2011.16; 2011.
2. Mukadi YD, Maher D, Harries A: Tuberculosis case fatality rates in high HIV
prevalence populations in sub-Saharan Africa. AIDS (London, Engl) 2001,
15(2):143–152.3. Zolopa A, Andersen J, Powderly W, Sanchez A, Sanne I, Suckow C, Hogg E,
Komarow L: Early antiretroviral therapy reduces AIDS progression/death
in individuals with acute opportunistic infections: a multicenter
randomized strategy trial. PloS One 2009, 4(5):e5575.
4. Dheda K, Lampe FC, Johnson MA, Lipman MC: Outcome of HIV-associated
tuberculosis in the era of highly active antiretroviral therapy. J Infect Dis
2004, 190(9):1670–1676.
5. Abdool Karim SS, Naidoo K, Grobler A, Padayatchi N, Baxter C, Gray A,
Gengiah T, Nair G, Bamber S, Singh A, et al: Timing of initiation of
antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010,
362(8):697–706.
6. Havlir DV, Kendall MA, Ive P, Kumwenda J, Swindells S, Qasba SS,
Luetkemeyer AF, Hogg E, Rooney JF, Wu X, et al: Timing of antiretroviral
therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011,
365(16):1482–1491.
7. Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, Nerrienet E, Madec Y,
Marcy O, Chan S, Prak N, et al: Earlier versus later start of antiretroviral
therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011,
365(16):1471–1481.
8. World Health Organisation: Antiretroviral drugs for treating pregnant women and
preventing HIV infections in infants: recommendations for public approach - 2010
revision. Geneva: World Health Organisation; 2010. http://whqlibdoc.who.int/
publications/2010/9789241599818_eng.pdf?ua=1.
9. World Health Organisation: Global tuberculosis control report 2013. Geneva:
World Health Organisation, WHO/HTM/TB/2013.15; 2013.
10. Malawi Ministry of Health: Integrated HIV program report: July - September
2012. Lilongwe Ministry of Health, HIV Department; 2012. http://www.
hivunitmohmw.org/uploads/Main/Quarterly_HIV_Programme_Report_
2012_Q3.pdf.
11. Lawn SD, Myer L, Edwards D, Bekker LG, Wood R: Short-term and long-term
risk of tuberculosis associated with CD4 cell recovery during antiretroviral
therapy in South Africa. AIDS (London, Engl) 2009, 23(13):1717–1725.
12. Lawn SD, Kranzer K, Wood R: Antiretroviral therapy for control of the
HIV-associated tuberculosis epidemic in resource-limited settings.
Clin Chest Med 2009, 30(4):685–699. viii.
13. Tuberculosis country profiles. https://extranet.who.int/sree/Reports?
op=Replet&name=%2FWHO_HQ_Reports%2FG2%2FPROD%2FEXT%
2FTBCountryProfile&ISO2=MW&outtype=html.
14. Clinical management of HIV in children and adults; integrated guidelines for
providing HIV services. http://www.hivunitmohmw.org/uploads/Main/Malawi
%20Integrated%20Guidelines%20for%20Clinical%20Management%20of%
20HIV%202011%20First%20Edition.pdf.
15. Phiri S, Khan PY, Grant AD, Gareta D, Tweya H, Kalulu M, Chaweza T,
Mbetewa L, Kanyerere H, Weigel R, et al: Integrated tuberculosis and HIV
care in a resource-limited setting: experience from the Martin Preuss
centre, Malawi. Trop Med Int Health 2011, 16(11):1397–1403.
16. Nglazi MD, Kaplan R, Caldwell J, Peton N, Lawn SD, Wood R, Bekker LG:
Antiretroviral treatment uptake in patients with HIV-associated TB
attending co-located TB and ART services. South Af Med J Suid 2012,
102(12):936–939.
17. Pepper DJ, Marais S, Wilkinson RJ, Bhaijee F, De Azevedo V, Meintjes G:
Barriers to initiation of antiretrovirals during antituberculosis therapy in
Africa. PloS One 2011, 6(5):e19484.
18. Autar RS, Wit FW, Sankote J, Mahanontharit A, Anekthananon T,
Mootsikapun P, Sujaikaew K, Cooper DA, Lange JM, Phanuphak P, et al:
Nevirapine plasma concentrations and concomitant use of rifampin in
patients coinfected with HIV-1 and tuberculosis. Antiviral Ther 2005, 10
(8):937–943.
19. Boulle A, Van Cutsem G, Cohen K, Hilderbrand K, Mathee S, Abrahams M,
Goemaere E, Coetzee D, Maartens G: Outcomes of nevirapine- and
efavirenz-based antiretroviral therapy when coadministered with
rifampicin-based antitubercular therapy. Jama 2008, 300(5):530–539.
20. van Oosterhout JJ, Kumwenda JJ, Beadsworth M, Mateyu G, Longwe T,
Burger DM, Zijlstra EE: Nevirapine-based antiretroviral therapy started
early in the course of tuberculosis treatment in adult Malawians. Antiviral
Ther 2007, 12(4):515–521.
21. Breen RA, Lipman MC, Johnson MA: Increased incidence of peripheral
neuropathy with co-administration of stavudine and isoniazid in
HIV-infected individuals. AIDS (London, Engl) 2000, 14(5):615.
22. Duran S, Spire B, Raffi F, Walter V, Bouhour D, Journot V, Cailleton V, Leport C,
Moatti JP: Self-reported symptoms after initiation of a protease inhibitor in
Tweya et al. BMC Public Health 2014, 14:183 Page 8 of 8
http://www.biomedcentral.com/1471-2458/14/183HIV-infected patients and their impact on adherence to HAART. HIV Clin
Trials 2001, 2(1):38–45.
23. Ammassari A, Murri R, Pezzotti P, Trotta MP, Ravasio L, De Longis P, Lo
Caputo S, Narciso P, Pauluzzi S, Carosi G, et al: Self-reported symptoms and
medication side effects influence adherence to highly active
antiretroviral therapy in persons with HIV infection. J Acquir Immun Def
Syndro (1999) 2001, 28(5):445–449.
doi:10.1186/1471-2458-14-183
Cite this article as: Tweya et al.: Timing of antiretroviral therapy and
regimen for HIV-infected patients with tuberculosis: the effect of revised
HIV guidelines in Malawi. BMC Public Health 2014 14:183.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
